Nemus Bioscience Inc (NMUS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nemus Bioscience Inc (NMUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9360
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nemus Bioscience Inc (Nemus Bioscience) is a life-science and biopharmaceutical company that offers discovering, developing and commercializing cannabinoid-based therapeutics. The company’s drug pipeline products include NB1111, NB1222, NB2111, NB2222 and Cannabinoid platform NB3111. Its cannabinoids comprise tetrahydrocannabinoal, cannabidiol, cannabinol, cannabichromene, cannbigerol and beta-caryophyllene, among others. Nemus Bioscience develops new chemical entities from a class of chemically diverse compounds called cannabinoids that molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. The company also develops novel and proprietary classes of product candidates that improve therapeutic options through enhanced chemical engineering and allow drug candidates to predictable bioavailability and pharmacokinetics. Nemus Bioscience is headquartered in Costa Mesa, California, the US.

Nemus Bioscience Inc (NMUS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nemus Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Nemus Bioscience Raises USD2.4 Million in Venture Financing 12
Nemus Bioscience Secures USD0.62 Million in Venture Funding from Tylt Lab 13
Partnerships 14
Nemus Bioscience Enters into Agreement with Albany Molecular 14
Nemus Bioscience Enters into Development Agreement with Nanomerics 15
NEMUS Bioscience Enters into Agreement with Catalent Pharma Solutions 16
Nemus Bioscience Enters into Agreement with Albany Molecular Research 17
Nemus Bioscience Enters into Research Agreement with University of Mississippi for CIPN 18
University of Mississippi and Nemus Enter into Research Agreement For Glaucoma Treatment 19
University of Mississippi and Nemus Enter into Research Agreement For CBD Formulations 20
Nemus Bioscience Enters into Research Agreement with University of Mississippi 21
Nemus Enters into Research Agreement with University of Mississippi for MRSA 22
Nemus Bioscience Enters into Research Agreement with University of Mississippi 23
Licensing Agreements 24
Nemus Bioscience Enters into Licensing Agreement University of Mississippi 24
Nemus Bioscience Enters into Licensing Agreement with Teewinot Life Sciences 25
Nemus Bioscience Enters into Licensing Agreement with University of Mississippi for UM 8930 26
Nemus Bioscience Renews its Option Agreement with University of Mississippi 27
Nemus Enters into Licensing Agreement with University of Mississippi for UM 1490, UM 5070 and UM 8790 28
Equity Offering 29
NEMUS Bioscience Raises USD1.75 Million in Private Placement of Shares 29
Nemus Bioscience to Raise Funds through Public Offering of Shares 30
Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 31
Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 32
Nemus Bioscience to Raise USD20 Million in Private Placement of Series E Preferred Stock 33
Nemus Bioscience Announces to Raise Funds through Public Offering of Shares 34
Nemus Bioscience Plans to Raise Funds through Public Offering of Shares 35
NEMUS Bioscience Raises USD1.2 Million in Private Placement of Preferred Stock 36
Nemus Bioscience Raises USD0.7 Million in Second Tranche of Private Placement of Series D Preferred Stock 37
Nemus Bioscience Raises USD0.5 Million in First Tranche of Private Placement of Series D Preferred Stock 38
Nemus Bioscience Raises USD0.5 Million in Private Placement of Preferred Stock Financing 39
Nemus Bioscience Raises USD5 Million in Private Placement of Series B Convertible Preferred Stock 40
Nemus Bioscience Raises USD1.5 Million in Private Placement of Series A Preferred Stock 42
Nemus Raises USD0.38 Million in Private Placement of Series A Preferred Shares 43
Nemus Bioscience Raises USD0.3 Million in Private Placement of Series A Preferred Shares 44
Nemus Bioscience Raises USD0.7 Million in Private Placement of Shares 45
Nemus Bioscience Inc – Key Competitors 46
Nemus Bioscience Inc – Key Employees 47
Nemus Bioscience Inc – Locations And Subsidiaries 48
Head Office 48
Recent Developments 49
Corporate Communications 49
May 07, 2018: Nemus Bioscience Adds to Senior Leadership Team 49
Product News 50
11/06/2017: NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) at Upcoming Scientific Meetings 50
11/06/2017: NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Ocular Diseases (NB2222) at Upcoming Scientific Meetings 51
08/07/2017: NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting 52
08/02/2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference 53
07/17/2017: Nemus Bioscience Announces NB2111 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting 54
06/22/2017: Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nemus Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nemus Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nemus Bioscience Raises USD2.4 Million in Venture Financing 12
Nemus Bioscience Secures USD0.62 Million in Venture Funding from Tylt Lab 13
Nemus Bioscience Enters into Agreement with Albany Molecular 14
Nemus Bioscience Enters into Development Agreement with Nanomerics 15
NEMUS Bioscience Enters into Agreement with Catalent Pharma Solutions 16
Nemus Bioscience Enters into Agreement with Albany Molecular Research 17
Nemus Bioscience Enters into Research Agreement with University of Mississippi for CIPN 18
University of Mississippi and Nemus Enter into Research Agreement For Glaucoma Treatment 19
University of Mississippi and Nemus Enter into Research Agreement For CBD Formulations 20
Nemus Bioscience Enters into Research Agreement with University of Mississippi 21
Nemus Enters into Research Agreement with University of Mississippi for MRSA 22
Nemus Bioscience Enters into Research Agreement with University of Mississippi 23
Nemus Bioscience Enters into Licensing Agreement University of Mississippi 24
Nemus Bioscience Enters into Licensing Agreement with Teewinot Life Sciences 25
Nemus Bioscience Enters into Licensing Agreement with University of Mississippi for UM 8930 26
Nemus Bioscience Renews its Option Agreement with University of Mississippi 27
Nemus Enters into Licensing Agreement with University of Mississippi for UM 1490, UM 5070 and UM 8790 28
NEMUS Bioscience Raises USD1.75 Million in Private Placement of Shares 29
Nemus Bioscience to Raise Funds through Public Offering of Shares 30
Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 31
Nemus Bioscience Raises USD2 Million in Private Placement of Series F Preferred Stock 32
Nemus Bioscience to Raise USD20 Million in Private Placement of Series E Preferred Stock 33
Nemus Bioscience Announces to Raise Funds through Public Offering of Shares 34
Nemus Bioscience Plans to Raise Funds through Public Offering of Shares 35
NEMUS Bioscience Raises USD1.2 Million in Private Placement of Preferred Stock 36
Nemus Bioscience Raises USD0.7 Million in Second Tranche of Private Placement of Series D Preferred Stock 37
Nemus Bioscience Raises USD0.5 Million in First Tranche of Private Placement of Series D Preferred Stock 38
Nemus Bioscience Raises USD0.5 Million in Private Placement of Preferred Stock Financing 39
Nemus Bioscience Raises USD5 Million in Private Placement of Series B Convertible Preferred Stock 40
Nemus Bioscience Raises USD1.5 Million in Private Placement of Series A Preferred Stock 42
Nemus Raises USD0.38 Million in Private Placement of Series A Preferred Shares 43
Nemus Bioscience Raises USD0.3 Million in Private Placement of Series A Preferred Shares 44
Nemus Bioscience Raises USD0.7 Million in Private Placement of Shares 45
Nemus Bioscience Inc, Key Competitors 46
Nemus Bioscience Inc, Key Employees 47

List of Figures
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nemus Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Nemus Bioscience Inc (NMUS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析
    Summary Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, …
  • Golden Star Resources Ltd:企業の戦略・SWOT・財務情報
    Golden Star Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Star Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Royal Mail Plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail Plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • JBCC Holdings Inc (9889):企業の財務・戦略的SWOT分析
    JBCC Holdings Inc (9889) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Definiens AG:医療機器:M&Aディール及び事業提携情報
    Summary Definiens AG (Definiens), a subsidiary of AstraZeneca Plc, is a healthcare technology company that offers image analysis and data mining solutions. The company offers products such as tissue studio, developer, image miner, server, architect and viewer, among others. Its services include cons …
  • Obalon Therapeutics Inc (OBLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Obalon Therapeutics Inc (Obalon Therapeutics) is a manufacturer of medical devices and equipment. The company offers development and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It also researches, designs, produces, and sells medical gast …
  • CTCI Corporation (9933)-エネルギー分野:企業M&A・提携分析
    Summary CTCI Corporation (CTCI) is an engineering, procurement, and construction services provider that operates along with its subsidiaries and affiliates. It offers construction services includes feasibility study, design, and fabrication; project related services: project management, supervision, …
  • Sunrise Senior Living LLC:企業の戦略・SWOT・財務情報
    Sunrise Senior Living LLC - Strategy, SWOT and Corporate Finance Report Summary Sunrise Senior Living LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Wipro Ltd:企業のM&A・事業提携・投資動向
    Wipro Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wipro Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • ITC Holdings Corp.:電力:M&Aディール及び事業提携情報
    Summary ITC Holdings Corp. (ITC Holdings), an indirect subsidiary of Fortis Inc, is an independent electricity transmission company. It owns, operates, maintains, and invests in transmission infrastructure. The company harnesses system integrity and reliability, reduces transmission constraints, all …
  • Prairie Land Electric Cooperative Inc:企業の戦略的SWOT分析
    Prairie Land Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Abivax SA (ABVX):企業の財務・戦略的SWOT分析
    Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce f …
  • Instituto Costarricense de Electricidad:企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • People’s Bank:企業の戦略・SWOT・財務情報
    People's Bank - Strategy, SWOT and Corporate Finance Report Summary People's Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Europ Assistance Holding SA:企業の戦略的SWOT分析
    Europ Assistance Holding SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Luxoft Holding Inc:企業の戦略・SWOT・財務分析
    Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report Summary Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • OraSure Technologies Inc (OSUR):医療機器:M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • FGL Sports Ltd. :企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Avraham Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Avraham Pharmaceuticals Ltd (Avraham Pharmaceuticals) is a pharmaceutical company that develops novel products for treatment and prevention of neurodegenerative disorders. The company offers a product, Ladostigil. It offers product in the therapeutic area of mild cognitive impairment. Avraha …
  • Institute of Organic Chemistry and Biochemistry AS CR vvi:製薬・医療:M&Aディール及び事業提携情報
    Summary Institute of Organic Chemistry and Biochemistry AS CR vvi (IOCB) is a research institute that offers organic chemistry and biochemistry for medical and environmental applications. The institute’s scientific research includes the fields of physico-organic chemistry and biochemistry, molecular …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆